StockData
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. (PLX) stock

PLXNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 16/3044% below fair value
$3.03−0.02 (-0.66%)

Close on Nov 16, 2026Market cap $244.13MP/E 13.2Yield –

Protalix BioTherapeutics cash

Cash and short-term investments held at the end of each period.

Protalix BioTherapeutics's cash was $27.42M at Jun 30, 2026. For fiscal 2025 it was $14.68M, down 25.7% from the year before. Over ten years it grew -15.2% a year on average. The highest annual figure on record is $86.40M in fiscal 2013.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$14.68M-25.7%
FY2024Dec 31, 2024$19.76M-16.4%
FY2023Dec 31, 2023$23.63M+38.1%
FY2022Dec 31, 2022$17.11M-56.1%
FY2021Dec 31, 2021$38.99M+113.4%
FY2020Dec 31, 2020$18.27M+2.7%
FY2019Dec 31, 2019$17.79M-52.9%
FY2018Dec 31, 2018$37.81M-26.1%
FY2017Dec 31, 2017$51.16M-19.1%
FY2016Dec 31, 2016$63.28M-17.1%
FY2015Dec 31, 2015$76.37M+39.5%
FY2014Dec 31, 2014$54.77M-36.6%
FY2013Dec 31, 2013$86.40M+66.0%
FY2012Dec 31, 2012$52.04M+92.7%
FY2011Dec 31, 2011$27.00M-24.8%
FY2010Dec 31, 2010$35.90M-55.8%
FY2009Dec 31, 2009$81.27M+90.8%
FY2008Dec 31, 2008$42.60M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$27.42M+53.2%
Q1 FY2026Mar 31, 2026$41.00M+110.7%
Q4 FY2025Dec 31, 2025$14.68M-25.7%
Q3 FY2025Sep 30, 2025$13.65M-50.2%
Q2 FY2025Jun 30, 2025$17.90M-23.5%
Q1 FY2025Mar 31, 2025$19.46M-28.5%
Q4 FY2024Dec 31, 2024$19.76M-16.4%
Q3 FY2024Sep 30, 2024$27.41M+34.3%
Q2 FY2024Jun 30, 2024$23.40M-51.4%
Q1 FY2024Mar 31, 2024$27.21M-17.6%
Q4 FY2023Dec 31, 2023$23.63M+38.1%
Q3 FY2023Sep 30, 2023$20.41M+90.4%
Q2 FY2023Jun 30, 2023$48.18M+285.7%
Q1 FY2023Mar 31, 2023$33.04M+95.6%
Q4 FY2022Dec 31, 2022$17.11M-56.1%
Q3 FY2022Sep 30, 2022$10.72M+0.7%
Q2 FY2022Jun 30, 2022$12.49M-63.1%
Q1 FY2022Mar 31, 2022$16.89M-14.8%
Q4 FY2021Dec 31, 2021$38.99M+113.4%
Q3 FY2021Sep 30, 2021$10.64M-21.4%
Q2 FY2021Jun 30, 2021$33.88M+139.2%
Q1 FY2021Mar 31, 2021$19.83M+11.5%
Q4 FY2020Dec 31, 2020$18.27M-14.8%
Q3 FY2020Sep 30, 2020$13.53M-46.1%
Q1 FY2020Mar 31, 2020$14.17M-53.3%
Q4 FY2019Dec 31, 2019$17.79M-52.9%
Q3 FY2019Sep 30, 2019$21.44M-48.8%
Q2 FY2019Jun 30, 2019$25.10M-11.4%
Q1 FY2019Mar 31, 2019$30.36M-26.5%
Q4 FY2018Dec 31, 2018$37.81M-26.1%
Q3 FY2018Sep 30, 2018$41.87M+25.0%
Q2 FY2018Jun 30, 2018$28.33M-18.0%
Q1 FY2018Mar 31, 2018$41.32M-13.9%
Q4 FY2017Dec 31, 2017$51.16M-19.1%
Q3 FY2017Sep 30, 2017$33.48M-34.8%
Q2 FY2017Jun 30, 2017$34.53M-36.8%
Q1 FY2017Mar 31, 2017$48.02M–
Q4 FY2016Dec 31, 2016$63.28M–
Q3 FY2016Sep 30, 2016$51.32M–
Q2 FY2016Jun 30, 2016$54.63M–

More Protalix BioTherapeutics figures

See a number that looks wrong?